FGFR2 and neoplasm: This molecular screening could avoid the prescription of these drugs to patients (including those with FGFR2 GAs) that are unlikely to respond to these treatments because of inactivated FGFR signalling in tumor tissue, with a significant reduction in terms of clinical and financial toxicities.